Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab for COVID-19-associated severe acute respiratory syndrome
RBR-5vpyh4Phase 2Recruiting
- Sponsor
- Pesquisador
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of secukinumab in coronavirus disease 2019 (COVID-19), pneumonia and severe acute respiratory syndrome (SARS) (2 arms), sponsored by Pesquisador. Started Aug 2020; status: recruiting.
02
Drugs
secukinumab
03
Conditions
coronavirus disease 2019 (COVID-19)pneumoniasevere acute respiratory syndrome (SARS)
Beyond the preview
Go deeper on RBR-5vpyh4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-5vpyh4.